Surveyed U.S. Physicians Indicate That Xarelto and Apixaban Will Benefit From
the Lack of Use of a Fast-Acting Injectable Anticoagulant in the Treatment and
Secondary Prophylaxis of Deep Vein Thrombosis/Pulmonary Embolism
Reducing the Incidence of Bleeding is One of the Greatest Unmet Needs in the
Treatment and Secondary Prophylaxis of Deep Vein Thrombosis/Pulmonary
Embolism, According to a New Report from Decision Resources
BURLINGTON, Mass., March 27, 2013
BURLINGTON, Mass., March 27, 2013 /PRNewswire/ -- Decision Resources, one of
the world's leading research and advisory firms for pharmaceutical and
healthcare issues, finds that clinical data and the opinions of interviewed
thought leaders indicate that there is little to distinguish between current
regimens utilized for the treatment and secondary prophylaxis of deep vein
thrombosis (DVT)/pulmonary embolism (PE), as these regimens are initiated with
use of a short-term injectable anticoagulant prior to long-term
anticoagulation with warfarin. However, Bayer/Janssen's Xarelto and
Bristol-Myers Squibb/Pfizer's Eliquis are expected to displace current
therapies for the treatment and secondary prophylaxis of DVT/PE. Surveyed U.S.
emergency room physicians indicate that Xarelto and Eliquis have competitive
advantages in efficacy, safety and tolerability and delivery.
(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )
"We forecast that Xarelto will become the U.S. market leader in the treatment
and secondary prophylaxis of DVT/PE, with a 22.4 percent patient share by
2021, closely followed by apixaban with 19.3 percent," said Decision Resources
Analyst Eamonn O'Connor, Ph.D. "This is due to these agents' impressive
results in clinical trials, and the fact that oral therapy can be initiated
straight away, removing the need to begin therapy with a fast-acting
The DecisionBase 2013 report entitled Therapies with Improved Safety and
Delivery Profiles Are Set to Overtake Enoxaparin and Warfarin as Leading
Treatments of DVT/PE also finds that surveyed U.S. and European emergency room
physicians agree that the incidence of VTE-related mortality is one of the
attributes that most influences their decisions regarding prescribing in the
treatment and secondary prophylaxis of DVT and PE. Clinical data and the
opinions of interviewed thought leaders indicate that current and emerging
therapies have no advantage on this attribute over the sales-leading regimen
of enoxaparin (Sanofi's Lovenox, generics) plus warfarin (Bristol-Myers
Squibb's Coumadin, Eisai's Warfarin, generics).
According to insights from surveyed U.S. and European emergency room
physicians and managed care organization (MCO) pharmacy directors, reducing
the incidence of bleeding is one of the greatest unmet needs in the treatment
and secondary prophylaxis of DVT/PE. Clinical data and the opinions of
interviewed thought leaders indicate that the novel oral anticoagulants --
Xarelto, Eliquis, Boehringer Ingelheim's Pradaxa, Daiichi Sankyo's Lixiana --
have demonstrated the potential to partially fulfill this unmet need.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market
research publications, advisory services and consulting designed to help
clients shape strategy, allocate resources and master their chosen markets.
Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group at
All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.
SOURCE Decision Resources
Contact: Christopher Comfort, Decision Resources, 781-993-2597,
Press spacebar to pause and continue. Press esc to stop.